A new clinical trial called ALSTARS is set to begin evaluating COYA 302, an investigational biologic therapy, as a potential treatment option for adults living with Amyotrophic Lateral Sclerosis (ALS). The study will be conducted at 20 to 25 sites across the United States and Canada, offering more patients access to cutting-edge research close to home.
COYA 302 combines two components: low dose interleukin-2 (LD IL-2) and DRL_AB, a biosimilar candidate for abatacept. Together, these are designed to work through a dual immunomodulatory mechanism, aiming to boost the anti-inflammatory activity of regulatory T cells while also calming inflammation driven by activated monocytes and macrophages. This approach reflects a growing scientific interest in addressing the immune and inflammatory components that may contribute to ALS progression.
The trial is structured thoughtfully, with participants randomly assigned to one of two COYA 302 dosing regimens or a placebo group during an initial 24-week double-blind period. Importantly, those who complete this phase will have the opportunity to continue into a 24-week extension period where they will receive one of the active COYA 302 regimens, giving more participants a chance to experience the investigational therapy over time.
Researchers will track meaningful, well-established measures of ALS progression, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament light chain levels, maximal inspiratory pressure, and slow vital capacity. These outcome measures are widely used in ALS research and should provide valuable insight into whether COYA 302 can meaningfully impact disease trajectory, in addition to standard safety monitoring throughout the study.
For the ALS community, every new well-designed clinical trial represents a step forward. ALS remains a challenging condition with limited treatment options, and studies like ALSTARS that explore novel immunomodulatory approaches offer hope for expanding the therapeutic toolkit available to patients and clinicians. As enrollment moves forward across multiple sites, the coming months and years of data collection will help clarify whether this combination therapy can offer real benefit to those affected by this disease.
This article is for informational purposes only and is not medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Clinical Trial: Study of COYA 302 for the Treatment of ALS
Leave a Reply